作者
Wilma T Anselmo-Lima, Fabrizio R Romano, Edwin Tamashiro, Renato Roithmann, Vanessa RP Dinarte, Otavio B Piltcher, Marcel M Miyake, Marco A Fornazieri, Marcio Nakanishi, Thiago FP Bezerra, Ricardo LL Dolci, João F Mello Jr, Marcus M Lessa, Richard L Voegels, Eduardo M Kosugi, Eulalia Sakano, Fabiana CP Valera
发表日期
2024/1/30
来源
Brazilian Journal of Otorhinolaryngology
页码范围
101394
出版商
Elsevier
简介
Introduction
Biologics targeting type 2 inflammation have revolutionized the way we treat patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). Particularly in severe and difficult-to-control cases, these drugs have provided a new reality for these patients, allowing for the effective and safe treatment of extensive diseases that were not completely managed with the typical strategy of surgery and topical medications.
Objectives
The experience achieved with the approval of these medications by ANVISA for use in CRSwNP and the knowledge obtained regarding outcomes, adverse effects, and the ideal patient profile prompted the update of the previously published guideline, with a detailed review of the most recent scientific literature, the personal experiences of experts, and the adaptation to the reality of the Brazilian healthcare system, both public and private.
Results
We proposed a new eligibility criterion …
学术搜索中的文章
WT Anselmo-Lima, FR Romano, E Tamashiro… - Brazilian Journal of Otorhinolaryngology, 2024